CAR-T 细胞疗法在实体瘤治疗中的挑战与优化策略
摘要
关键词
全文:
PDF镜像
|参考
Smirnov S, et al. Advancing CAR-T Therapy for Solid Tumors: From Barriers to Clinical Progress. Biomolecules. 2025;15(10):1407.
Alsinhani A, et al. CAR-T cells in solid tumors: engineering, biomarkers, translational pathways and the road ahead. Front Immunol. 2026;17:1796675.
Yao ZR, Kang K, et al. Dual-targeting CD133/PD-L1 CAR-T plus αPD-1 overcomes immunosuppressive microenvironment and enhanced by radiation pre-conditioning. Mol Ther. 2026.
Mahajna S, et al. Bioengineering CAR-T cells to function in hostile tumor microenvironments. Trends Biotechnol. 2026. doi: 10.1016/j.tibtech.2026.04.023.
Kim YJ, et al. Next-Generation CAR-T and TCR-T Cell Therapies for Solid Tumors: Innovations, Challenges, and Global Development Trends. Cancers. 2025;17(12):1945.
Chen L, et al. NR2F6 deletion revives CAR-T cell function and induces antigen-agnostic immune memory in solid tumors. Nat Commun. 2026;17:3264.
Weber EW, et al. Mapping the clinical landscape of multifunctional CAR T cells: Targets, trends, and synergies. Mol Ther. 2026;34(5):2590-2610.
Sterner RC, Sterner RM. Current state of CAR-T cell therapies for solid tumors. Mol Ther Methods Clin Dev. 2026;7:101028.
Zhang Q, et al. Advancements and challenges in CAR-T cell therapy for solid tumors: A comprehensive review of antigen targets, strategies, and future directions. Cancer Cell Int. 2025;25:313.
Nguyen H, Liang FS. Leveraging cell’s endogenous regulatory network: towards safer and more effective CAR T cell therapies for solid tumors. Transl Cancer Res. 2026;15(1):2.
(0 摘要 Views, 0 PDF Downloads)
Refbacks
- 当前没有refback。